Introduction:
TriLink BioTechnologies plans to open a state-of-the-art facility dedicated to late-phase mRNA drug substance production in the United States.
Features:
The 32,000-square-foot facility is meticulously crafted for mRNA manufacturing, serving as a dedicated hub to assist late-phase drug developers, spanning from phase 2 trials to commercialisation, with its robust mRNA manufacturing capabilities.
The facility is equipped with separate Grade C cleanroom suites dedicated to mRNA manufacturing, offering expanded mRNA capacity ranging from 1g to over 100g per batch.
Additionally, it provides comprehensive in-house analytical services and laboratory space for conducting on-site quality control testing.
The manufacturing suites are equipped with cutting-edge equipment and poised to meet late-phase manufacturing requirements.
This facility is anticipated to drive significant advancements in life-saving mRNA therapeutics.
This new facility advances the field by playing a pivotal role in advancing mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.
The opening is anticipated to drive the advancement of mRNA-based medicine for an expanding array of indications.
Specifications:
Name TriLink BioTechnologies
Type New Construction
